Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
NeoGenomics
(NASDAQ:NEO)
Intraday
$15.20
0
[0.00%]
After-Hours
$15.20
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$15.20
0
[0.00%]
At close: Mar 27
$15.20
0
[0.00%]
PreMarket: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for NeoGenomics Stock (NASDAQ:NEO)
NeoGenomics Stock (NASDAQ: NEO)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, March 18, 2024
What 6 Analyst Ratings Have To Say About NeoGenomics
Benzinga Insights
-
Mar 18, 2024, 2:00PM
Friday, March 15, 2024
Earnings Scheduled For March 15, 2024
Benzinga Insights
-
Mar 15, 2024, 5:15AM
Monday, February 26, 2024
Piper Sandler Maintains Overweight on NeoGenomics, Raises Price Target to $20
Benzinga Newsdesk
-
Feb 26, 2024, 9:52AM
Thursday, February 22, 2024
Goldman Sachs Maintains Buy Rating for NeoGenomics: Here's What You Need To Know
Benzinga Insights
-
Feb 22, 2024, 12:00PM
Wednesday, February 21, 2024
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Feb 21, 2024, 1:50PM
Why Is Cancer Genetics Test-Focused NeoGenomics Stock Trading Higher Today?
Vandana Singh
-
Feb 21, 2024, 11:01AM
Toll Brothers Posts Upbeat Earnings, Joins Exelon, Garmin, Bausch + Lomb And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
-
Feb 21, 2024, 10:47AM
NeoGenomics shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY24 adjusted EPS guidance above estimates.
Benzinga Newsdesk
-
Feb 21, 2024, 8:38AM
Why NeoGenomics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Feb 21, 2024, 8:06AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Feb 21, 2024, 8:06AM
Evaluating NeoGenomics: Insights From 4 Financial Analysts
Benzinga Insights
-
Feb 21, 2024, 7:00AM
Needham Maintains Buy on NeoGenomics, Raises Price Target to $24
Benzinga Newsdesk
-
Feb 21, 2024, 5:32AM
Tuesday, February 20, 2024
NeoGenomics shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY24 adjusted EPS guidance above estimates.
Benzinga Newsdesk
-
Feb 20, 2024, 5:06PM
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Feb 20, 2024, 4:31PM
NeoGenomics Sees FY24 Adj. EPS $0.04 Vs $(0.08) Est.
Benzinga Newsdesk
-
Feb 20, 2024, 4:27PM
Recap: NeoGenomics Q4 Earnings
Benzinga Insights
-
Feb 20, 2024, 4:10PM
NeoGenomics Q4 2023 Adj EPS $0.03 Beats $(0.02) Estimate, Sales $155.55M Beat $152.54M Estimate
Benzinga Newsdesk
-
Feb 20, 2024, 4:09PM
Earnings Scheduled For February 20, 2024
Benzinga Insights
-
Feb 20, 2024, 6:52AM
Monday, February 19, 2024
NeoGenomics's Earnings Outlook
Benzinga Insights
-
Feb 19, 2024, 3:01PM
Thursday, February 01, 2024
NeoGenomics Says It Signed For Working With Cancer Pledge In Support of Employees
Benzinga Newsdesk
-
Feb 1, 2024, 7:17AM
Friday, December 29, 2023
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Chris Katje
-
Dec 29, 2023, 11:04AM
Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday
Avi Kapoor
-
Dec 29, 2023, 9:20AM
TD Cowen Maintains Outperform on NeoGenomics, Lowers Price Target to $19
Benzinga Newsdesk
-
Dec 29, 2023, 8:40AM
BTIG Maintains Buy on NeoGenomics, Lowers Price Target to $21
Benzinga Newsdesk
-
Dec 29, 2023, 7:19AM
Thursday, December 28, 2023
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Dec 28, 2023, 1:07PM
US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In Lawsuit
Vandana Singh
-
Dec 28, 2023, 12:57PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Dec 28, 2023, 12:31PM
NeoGenomics, Energy Fuels And Other Big Stocks Moving Lower On Thursday
Avi Kapoor
-
Dec 28, 2023, 10:53AM
7 Analysts Have This To Say About NeoGenomics
Benzinga Insights
-
Dec 28, 2023, 10:00AM
Needham Reiterates Buy on NeoGenomics, Maintains $21 Price Target
Benzinga Newsdesk
-
Dec 28, 2023, 9:05AM
NeoGenomics shares are trading lower after Natera won a preliminary injuction in a patent infringement lawsuit against NeoGenomics' RaDar test.
Benzinga Newsdesk
-
Dec 28, 2023, 9:02AM
NeoGenomics Announced That Subsidiary Neogenomics Laboratories Will Appeal The Preliminary Injunction Issued By The U.S. District Court For The Middle District Of North Carolina
Benzinga Newsdesk
-
Dec 28, 2023, 8:13AM
Natera Wins Preliminary Injunction In Patent Infringement Lawsuit Against NeoGenomics' RaDaR Test
Benzinga Newsdesk
-
Dec 28, 2023, 2:02AM
Tuesday, December 05, 2023
NeoGenomics To Present New Data At San Antonio Breast Cancer Symposium Highlighting Utility Of RaDaR For Therapy Response
Benzinga Newsdesk
-
Dec 5, 2023, 8:04AM
Wednesday, November 08, 2023
Morgan Stanley Maintains Equal-Weight on NeoGenomics, Raises Price Target to $17
Benzinga Newsdesk
-
Nov 8, 2023, 4:25PM
Tuesday, November 07, 2023
What 6 Analyst Ratings Have To Say About NeoGenomics
Benzinga Insights
-
Nov 7, 2023, 4:00PM
Needham Reiterates Buy on NeoGenomics, Maintains $21 Price Target
Benzinga Newsdesk
-
Nov 7, 2023, 5:51AM
Monday, November 06, 2023
NeoGenomics Q3 2023 Sales $151.95M Beat $142.00M Estimate
Benzinga Newsdesk
-
Nov 6, 2023, 5:26PM
NeoGenomics Sees FY23 Revenue $585M-$592M Vs $573.19M Est.
Benzinga Newsdesk
-
Nov 6, 2023, 4:49PM
NeoGenomics Q3 EPS $0 Beats $(0.07) Estimate, Sales $152.00M Beat $141.65 Estimate
Benzinga Newsdesk
-
Nov 6, 2023, 4:47PM
Earnings Scheduled For November 6, 2023
Benzinga Insights
-
Nov 6, 2023, 8:24AM
Tuesday, October 24, 2023
Morgan Stanley Maintains Equal-Weight on NeoGenomics, Lowers Price Target to $16
Benzinga Newsdesk
-
Oct 24, 2023, 8:31AM
NeoGenomics Announces Commercial Availability Of Two New Tests
Benzinga Newsdesk
-
Oct 24, 2023, 7:09AM
Monday, October 23, 2023
Goldman Sachs Maintains Buy on NeoGenomics, Lowers Price Target to $17
Benzinga Newsdesk
-
Oct 23, 2023, 9:00AM
Friday, October 20, 2023
Goldman Sachs Maintains Buy on NeoGenomics, Lowers Price Target to $17
Benzinga Newsdesk
-
Oct 20, 2023, 9:50AM
Monday, October 16, 2023
Where NeoGenomics Stands With Analysts
Benzinga Insights
-
Oct 16, 2023, 3:00PM
Piper Sandler Maintains Overweight on NeoGenomics, Lowers Price Target to $18
Benzinga Newsdesk
-
Oct 16, 2023, 1:30PM
Friday, September 08, 2023
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Sep 8, 2023, 1:35PM
Monday, August 21, 2023
4 Analysts Have This to Say About NeoGenomics
Benzinga Insights
-
Aug 21, 2023, 2:00PM
Stephens & Co. Upgrades NeoGenomics to Overweight, Raises Price Target to $18
Benzinga Newsdesk
-
Aug 21, 2023, 11:25AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch